JP2016512521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512521A5 JP2016512521A5 JP2016501191A JP2016501191A JP2016512521A5 JP 2016512521 A5 JP2016512521 A5 JP 2016512521A5 JP 2016501191 A JP2016501191 A JP 2016501191A JP 2016501191 A JP2016501191 A JP 2016501191A JP 2016512521 A5 JP2016512521 A5 JP 2016512521A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- substituted
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 34
- 102000036639 antigens Human genes 0.000 claims 34
- 108091007433 antigens Proteins 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 34
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 13
- 238000006467 substitution reaction Methods 0.000 claims 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims 2
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 claims 2
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776430P | 2013-03-11 | 2013-03-11 | |
| US61/776,430 | 2013-03-11 | ||
| PCT/US2014/023274 WO2014164709A2 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512521A JP2016512521A (ja) | 2016-04-28 |
| JP2016512521A5 true JP2016512521A5 (enExample) | 2017-02-23 |
| JP6495884B2 JP6495884B2 (ja) | 2019-04-03 |
Family
ID=51659302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501191A Active JP6495884B2 (ja) | 2013-03-11 | 2014-03-11 | 改変抗ｔｇｆベータ抗体および抗原結合フラグメント |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9783604B2 (enExample) |
| EP (2) | EP3415633B1 (enExample) |
| JP (1) | JP6495884B2 (enExample) |
| KR (1) | KR102258457B1 (enExample) |
| CN (1) | CN105229160B (enExample) |
| AR (1) | AR095240A1 (enExample) |
| AU (2) | AU2014249051B2 (enExample) |
| BR (1) | BR112015021595A2 (enExample) |
| CA (1) | CA2904847C (enExample) |
| CY (1) | CY1121412T1 (enExample) |
| DK (1) | DK2971048T3 (enExample) |
| ES (2) | ES2845215T3 (enExample) |
| HR (1) | HRP20190201T1 (enExample) |
| HU (1) | HUE042020T2 (enExample) |
| IL (1) | IL241404B (enExample) |
| LT (1) | LT2971048T (enExample) |
| MX (1) | MX365385B (enExample) |
| PL (1) | PL2971048T3 (enExample) |
| PT (1) | PT2971048T (enExample) |
| RU (1) | RU2681502C2 (enExample) |
| SG (2) | SG11201507279XA (enExample) |
| SI (1) | SI2971048T1 (enExample) |
| TR (1) | TR201901415T4 (enExample) |
| TW (2) | TWI613216B (enExample) |
| UY (1) | UY35384A (enExample) |
| WO (1) | WO2014164709A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) * | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| DK3368571T5 (da) * | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| EP4036120A1 (en) * | 2015-10-30 | 2022-08-03 | F. Hoffmann-La Roche AG | Hinge modified antibody fragments and methods of making |
| JP7359547B2 (ja) | 2016-05-17 | 2023-10-11 | ジェネンテック， インコーポレイテッド | 免疫療法における診断及び使用のための間質遺伝子シグネチャー |
| GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
| EP3496755A4 (en) * | 2016-08-11 | 2020-03-11 | Precithera, Inc. | CONJUGATES OF TGF- ANTAGONISTS. |
| KR20190057308A (ko) | 2016-09-02 | 2019-05-28 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물 |
| CN110785431B (zh) | 2017-05-04 | 2024-05-07 | 阿塞勒隆制药公司 | TGF-β受体II型融合蛋白及其用途 |
| WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| AU2019302679A1 (en) * | 2018-07-11 | 2021-02-11 | Scholar Rock, Inc. | High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof |
| CN120025435A (zh) | 2019-08-28 | 2025-05-23 | 中外制药株式会社 | 跨物种抗潜伏TGF-β1抗体和使用方法 |
| TW202130655A (zh) | 2019-10-23 | 2021-08-16 | 美商庫爾生物製藥有限公司 | ＴＧＦ—β多肽 |
| PE20230259A1 (es) * | 2020-03-19 | 2023-02-07 | Genentech Inc | Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| WO2022115611A1 (en) | 2020-11-25 | 2022-06-02 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| WO2022157773A2 (en) * | 2021-01-21 | 2022-07-28 | Biolojic Design Ltd. | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof |
| CN112851819B (zh) * | 2021-01-25 | 2023-08-11 | 华中科技大学同济医学院附属同济医院 | 结合小鼠PD-L1和TGF-β的双特异性抗体及其制备方法与应用 |
| MX2023009497A (es) * | 2021-02-15 | 2023-08-23 | Takeda Pharmaceuticals Co | Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta). |
| CN113480645B (zh) * | 2021-07-16 | 2022-11-11 | 甘肃中科博瑞生物工程有限公司 | 一种抗幽门螺旋杆菌重组抗体、制备方法及用途 |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| EP4599089A1 (en) | 2022-10-05 | 2025-08-13 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| CA2122491A1 (en) | 1991-10-31 | 1993-05-13 | Herbert Y. Lin | Tgf-.beta. type receptor cdnas and uses therefor |
| US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| RU2157406C2 (ru) * | 1993-08-10 | 2000-10-10 | Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх | НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА |
| IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| WO2000040227A2 (en) | 1999-01-05 | 2000-07-13 | University Of Utah | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| DK1263464T3 (da) | 2000-03-09 | 2013-01-28 | Genzyme Corp | Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion |
| BRPI0307070A2 (pt) | 2002-01-22 | 2019-03-26 | Genzyme Corporation | uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| EP3520815B1 (en) | 2005-02-08 | 2021-11-17 | Genzyme Corporation | Antibodies to tgfbeta |
| WO2007050793A2 (en) | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| PL2012814T3 (pl) | 2006-04-12 | 2013-10-31 | Genzyme Corp | Sposoby leczenia chorób autoimmunologicznych |
| PL2918288T3 (pl) | 2006-10-03 | 2018-02-28 | Genzyme Corporation | Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej |
| ES2702049T3 (es) | 2009-04-24 | 2019-02-27 | Univ Vanderbilt | Inducción anti-TGF-beta de crecimiento óseo |
| US8911736B2 (en) | 2010-03-12 | 2014-12-16 | Genzyme Corporation | Combination therapy for treating breast cancer |
| WO2012030394A1 (en) | 2010-09-01 | 2012-03-08 | Genzyme Corporation | Treatment of myocardial infarction using tgf - beta antagonists |
-
2014
- 2014-03-11 BR BR112015021595A patent/BR112015021595A2/pt not_active IP Right Cessation
- 2014-03-11 MX MX2015012541A patent/MX365385B/es active IP Right Grant
- 2014-03-11 US US14/773,950 patent/US9783604B2/en active Active
- 2014-03-11 ES ES18181808T patent/ES2845215T3/es active Active
- 2014-03-11 EP EP18181808.9A patent/EP3415633B1/en active Active
- 2014-03-11 TR TR2019/01415T patent/TR201901415T4/tr unknown
- 2014-03-11 JP JP2016501191A patent/JP6495884B2/ja active Active
- 2014-03-11 DK DK14779440.8T patent/DK2971048T3/en active
- 2014-03-11 SI SI201431071T patent/SI2971048T1/sl unknown
- 2014-03-11 PL PL14779440T patent/PL2971048T3/pl unknown
- 2014-03-11 EP EP14779440.8A patent/EP2971048B1/en active Active
- 2014-03-11 UY UY0001035384A patent/UY35384A/es not_active Application Discontinuation
- 2014-03-11 SG SG11201507279XA patent/SG11201507279XA/en unknown
- 2014-03-11 HU HUE14779440A patent/HUE042020T2/hu unknown
- 2014-03-11 TW TW103108359A patent/TWI613216B/zh active
- 2014-03-11 HR HRP20190201TT patent/HRP20190201T1/hr unknown
- 2014-03-11 RU RU2015143156A patent/RU2681502C2/ru active
- 2014-03-11 SG SG10201707021RA patent/SG10201707021RA/en unknown
- 2014-03-11 KR KR1020157027607A patent/KR102258457B1/ko active Active
- 2014-03-11 WO PCT/US2014/023274 patent/WO2014164709A2/en not_active Ceased
- 2014-03-11 LT LTEP14779440.8T patent/LT2971048T/lt unknown
- 2014-03-11 AR ARP140100849A patent/AR095240A1/es not_active Application Discontinuation
- 2014-03-11 AU AU2014249051A patent/AU2014249051B2/en active Active
- 2014-03-11 CA CA2904847A patent/CA2904847C/en active Active
- 2014-03-11 ES ES14779440T patent/ES2713505T3/es active Active
- 2014-03-11 TW TW106136054A patent/TWI664979B/zh active
- 2014-03-11 CN CN201480026283.5A patent/CN105229160B/zh active Active
- 2014-03-11 PT PT14779440T patent/PT2971048T/pt unknown
-
2015
- 2015-09-09 IL IL241404A patent/IL241404B/en active IP Right Grant
-
2017
- 2017-08-07 US US15/670,631 patent/US10730936B2/en active Active
-
2018
- 2018-05-10 AU AU2018203261A patent/AU2018203261B2/en active Active
-
2019
- 2019-01-31 CY CY20191100139T patent/CY1121412T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512521A5 (enExample) | ||
| RU2015143156A (ru) | Сконструированные анти-tgf-бета антитела и антиген-связывающие фрагменты | |
| JP2016512551A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2018516853A5 (enExample) | ||
| JP2017501711A5 (enExample) | ||
| JP2020517249A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP2014205674A5 (enExample) | ||
| JP2019514844A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2010523592A5 (enExample) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2017149720A5 (enExample) | ||
| JP2015504421A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2018510636A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2016507523A5 (enExample) | ||
| JP2017504578A5 (enExample) |